INDEGENE Financial Statement Analysis
|
||
|
The Revenues of INDEGENE have increased by 12.29% YoY .
The Earnings Per Share (EPS) of INDEGENE has increased by 26.31 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
INDEGENE Last 5 Annual Financial Results
[BOM: 544172|NSE : INDGN]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹2,590 Cr | ₹2,306 Cr | ₹1,665 Cr | ₹966 Cr | ₹643 Cr |
| Expenses | ₹2,084 Cr | ₹1,910 Cr | ₹1,378 Cr | ₹736 Cr | ₹499 Cr |
| Operating Profit (Excl OI) | ₹505 Cr | ₹396 Cr | ₹287 Cr | ₹231 Cr | ₹144 Cr |
| Other Income | ₹76 Cr | ₹58 Cr | ₹26 Cr | ₹31 Cr | ₹3.50 Cr |
| Interest | ₹49 Cr | ₹31 Cr | ₹5.96 Cr | ₹6.96 Cr | ₹8.80 Cr |
| Depreciation | ₹76 Cr | ₹60 Cr | ₹33 Cr | ₹26 Cr | ₹19 Cr |
| Profit Before Tax | ₹459 Cr | ₹363 Cr | ₹226 Cr | ₹231 Cr | ₹75 Cr |
| Profit After Tax | ₹337 Cr | ₹266 Cr | ₹163 Cr | ₹186 Cr | ₹49 Cr |
| Consolidated Net Profit | ₹337 Cr | ₹266 Cr | ₹165 Cr | ₹149 Cr | ₹-6.30 Cr |
| Earnings Per Share (Rs) | ₹15.17 | ₹12.01 | ₹938.81 | ₹954.66 | ₹-40.26 |
| PAT Margin (%) | 13.00 | 11.54 | 9.78 | 19.22 | 7.65 |
| ROE(%) | 27.56 | 29.50 | 30.20 | 176.32 | 0.00 |
| ROCE(%) | 30.88 | 35.20 | 41.09 | 68.54 | 29.65 |
| Total Debt/Equity(x) | 0.29 | 0.38 | 0.02 | 0.08 | -4.12 |
Key Financials |
||
| Market Cap | : | ₹ 13,346.4 Cr |
| Revenue (TTM) | : | ₹ 2,756.7 Cr |
| Net Profit(TTM) | : | ₹ 383.9 Cr |
| EPS (TTM) | : | ₹ 16.0 |
| P/E (TTM) | : | 34.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INDEGENE | -3.8% | 5.3% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | -1.5% | 9.1% | 9.1% |
| DIVIS LABORATORIES | -4.9% | -0.6% | 59.1% |
| CIPLA | -1.8% | 1% | 0.5% |
| TORRENT PHARMACEUTICALS | 1.6% | 12.1% | 21.8% |
| DR REDDYS LABORATORIES | -3% | -0.9% | -7.7% |
| MANKIND PHARMA | 1.1% | 7.6% | 1.3% |
| ZYDUS LIFESCIENCES | -2.2% | -0.6% | -9.3% |
| LUPIN | -2.7% | 1% | 30.1% |
INDEGENE Revenues
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 12.29 % |
| 5 Yr CAGR | 41.67 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,590 Cr | 12.29 | |
| Mar2023 | ₹2,306 Cr | 38.54 | |
| Mar2022 | ₹1,665 Cr | 72.27 | |
| Mar2021 | ₹966 Cr | 50.30 | |
| Mar2020 | ₹643 Cr | - | |
INDEGENE Operating Profit
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 27.66 % |
| 5 Yr CAGR | 36.97 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹505 Cr | 27.66 | |
| Mar2023 | ₹396 Cr | 37.98 | |
| Mar2022 | ₹287 Cr | 24.46 | |
| Mar2021 | ₹231 Cr | 60.54 | |
| Mar2020 | ₹144 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 13.69 % |
| 5 Yr CAGR | -3.32 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 19.52% | 13.69 | |
| Mar2023 | 17.17% | -0.41 | |
| Mar2022 | 17.24% | -27.75 | |
| Mar2021 | 23.86% | 6.80 | |
| Mar2020 | 22.34% | - | |
INDEGENE Profit After Tax
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 26.53 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹337 Cr | 26.53 | |
| Mar2023 | ₹266 Cr | 61.51 | |
| Mar2022 | ₹165 Cr | 10.28 | |
| Mar2021 | ₹149 Cr | Positive | |
| Mar2020 | ₹-6.30 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 12.65 % |
| 5 Yr CAGR | 14.17 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 13 % | 12.65 | |
| Mar2023 | 11.54 % | 18.00 | |
| Mar2022 | 9.78 % | -49.12 | |
| Mar2021 | 19.22 % | 151.24 | |
| Mar2020 | 7.65 % | - | |
INDEGENE Earnings Per Share (EPS)
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 26.31 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹15 | 26.31 | |
| Mar2023 | ₹12 | -98.72 | |
| Mar2022 | ₹939 | -1.66 | |
| Mar2021 | ₹955 | Positive | |
| Mar2020 | ₹-40 | - | |
INDEGENE Return on Capital Employed (ROCE)
[BOM: 544172|NSE : INDGN]
| Y-o-Y | -12.27 % |
| 5 Yr CAGR | 1.02 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 30.88% | -12.27 | |
| Mar2023 | 35.2% | -14.33 | |
| Mar2022 | 41.09% | -40.05 | |
| Mar2021 | 68.54% | 131.16 | |
| Mar2020 | 29.65% | - | |
INDEGENE Share Price vs Sensex
| Current Share Price | : | ₹556.1 |
| Current MarketCap | : | ₹ 13,346.4 Cr |
| Updated EOD on | : | Apr 04,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDEGENE | -3.8% |
5.3% |
|
| SENSEX | -2.9% |
3.1% |
1.8% |
INDEGENE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | NA | 7% | 4.8% |
| BSE SMALLCAP | -2% | 7.2% | 3.2% |
| BSE HEALTHCARE | -2.3% | 5.7% | 14.3% |
| BSE SELECT IPO INDEX | -2.4% | 6% | NA |
| BSE MIDSMALLCAP | -2.6% | 6% | 2.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 250 | -2.2% | 7.5% | 0.1% |
| NIFTY MIDSMALLCAP 400 | -2.5% | 5.9% | 2.1% |
| NIFTY500 MULTICAP 50:25:25 | -2.7% | 5.1% | 1.8% |
| NIFTY TOTAL MARKET | -2.8% | 4.6% | 1.6% |
| NIFTY 500 | -2.8% | 4.6% | 1.5% |
You may also like the below Video Courses
FAQ about INDEGENE Financials
How the annual revenues of INDEGENE have changed ?
The Revenues of INDEGENE have increased by 12.29% YoY .
How the Earnings per Share (EPS) of INDEGENE have changed?
The Earnings Per Share (EPS) of INDEGENE has increased by 26.31 % YoY .
Check out Intrinsic Value of Peers of INDEGENE
Compare Stock Analytics of Peers of INDEGENE
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
